- Home
- TROX vs CVAC Comparison
TROX vs CVAC Comparison
Compare TROX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROX
- CVAC
- Stock Information
- Founded
- TROX 2018
- CVAC 2000
- Country
- TROX United States
- CVAC Germany
- Employees
- TROX N/A
- CVAC N/A
- Industry
- TROX Major Chemicals
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- TROX Industrials
- CVAC Health Care
- Exchange
- TROX Nasdaq
- CVAC Nasdaq
- Market Cap
- TROX 786.0M
- CVAC 764.4M
- IPO Year
- TROX 2005
- CVAC 2020
- Fundamental
- Price
- TROX $5.88
- CVAC $4.41
- Analyst Decision
- TROX Buy
- CVAC Strong Buy
- Analyst Count
- TROX 8
- CVAC 2
- Target Price
- TROX $8.13
- CVAC $11.00
- AVG Volume (30 Days)
- TROX 3.6M
- CVAC 778.2K
- Earning Date
- TROX 07-31-2025
- CVAC 05-20-2025
- Dividend Yield
- TROX 8.52%
- CVAC N/A
- EPS Growth
- TROX N/A
- CVAC N/A
- EPS
- TROX N/A
- CVAC 0.87
- Revenue
- TROX $3,038,000,000.00
- CVAC $566,039,775.00
- Revenue This Year
- TROX $2.83
- CVAC N/A
- Revenue Next Year
- TROX $5.03
- CVAC $29.35
- P/E Ratio
- TROX N/A
- CVAC $5.08
- Revenue Growth
- TROX 4.18
- CVAC 787.60
- 52 Week Low
- TROX $4.35
- CVAC $2.37
- 52 Week High
- TROX $20.29
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- TROX 57.46
- CVAC 60.06
- Support Level
- TROX $5.22
- CVAC $4.31
- Resistance Level
- TROX $5.76
- CVAC $4.82
- Average True Range (ATR)
- TROX 0.30
- CVAC 0.29
- MACD
- TROX 0.11
- CVAC 0.01
- Stochastic Oscillator
- TROX 88.85
- CVAC 64.04
About TROX Tronox Holdings plc (UK)
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.